ROIV

Announcements

Nothing here yet

Daily updates

• Roivant's Phase 2 PHocus trial showed significant pulmonary vascular resistance and functional improvementsSep 8, 2026

FDA designations

• Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)Sep 4, 2025

News

• Immunovant reports topline results from a proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosusSep 23, 2026
• Roivant reported positive PHocus study results for mosliciguat in PH-ILD and disclosed its ongoing Phase 3 PHrontier studySep 8, 2026
• Priovant received FDA approval for LISRAYA (brepocitinib) for adults with dermatomyositis, now available in the U.S.Aug 28, 2026
• JAMA Dermatology published skin-specific outcomes from the Phase 3 VALOR trial of brepocitinib in dermatomyositisAug 26, 2026
• Priovant enrolled the first patients in the Phase 3 BEACON+ study of brepocitinib for cutaneous sarcoidosisAug 6, 2026